Introduction
============

Breast cancer (BC) is the most prevalent form of cancer in women worldwide. In Brazil, BC is a significant public health problem due to its morbidity, and high incidence and mortality rates. It is the first cause of cancer-related deaths in women of all ages, about half of the affected women are diagnosed in advanced stages of the disease and, not surprisingly, mortality rates are still increasing. Porto Alegre, Brazil\'s southernmost capital, has one of the highest BC incidence rates in the country, estimated at 125 per 100,000 individuals for the year 2012 as compared to the average national rate of 52 per 100,000 individuals ([@B01]).

Polymorphisms in genes coding for hormone receptors have been linked to modifications in reproductive factors and to an increased BC risk in different populations. Among these, estrogen receptor (*ER*) and progesterone receptor (*PGR*) genes have been extensively studied in different populations.

Estrogen receptor
-----------------

In the breast, estrogens bind to specific receptors with high affinity, triggering DNA synthesis, cell division, and proliferation of the breast epithelial cells. Two types of ERs have been identified, *ERα* and *Erβ*, and the former, also named *ESR1*, is an important mediator of hormonal response in estrogen-sensitive tissues such as breast, endometrium, and bone ([@B02],[@B03]). The *ERα* gene has been mapped to 6q25.1 and its two most commonly described single nucleotide polymorphisms are *ERα-397 PvuII C/T* (rs2234693) and *ERα-351 XbaI A/G* (rs9340799). Both are in strong linkage disequilibrium and have been associated with hormonal modifications and increase BC risk ([@B03]).

*ERα-397 C/T polymorphism*. Some studies have reported an increase BC risk associated with the *ERα-397 T* allele, and have suggested that this allele modulates the effect of hormone replacement therapy (HRT) on mammographic density and is independently associated with increased mammographic density ([@B02]-[@B06]). In addition, the *ERα-397 TT* genotype has been associated with an increased risk of BC diagnosis at a younger age, associated with a higher number of pregnancies, later age at menarche and use of oral contraceptives, and some studies have suggested that this genotype is more frequent in women with a positive family history of the disease ([@B04],[@B07]).

*ERα-351 XbaI A/G polymorphism*. Some investigators have suggested that the *ERα-351 A* allele modulates the effect of HRT on mammographic density, and an independent study by the same authors demonstrated an association between the *ERα-351 A* allele and increased mammographic density regardless of HRT ([@B04]). The *ERα-351 AA* genotype was associated with a slight increase in body mass index (BMI), which could ultimately influence BC risk ([@B04]). Finally, a few haplotype studies involving both the *ERα-397 PvuII C/T* and *ERα-351 XbaI A/G* polymorphisms have indicated that the increase in BC risk may be particularly significant in the presence of certain haplotypes, such as the *ERα-397-ERα-351A-A-T-T* haplotype, that is associated with a relative risk for BC of 1.5 ([@B03],[@B08]). There is no report on the genotypic and/or allelic frequencies of the *ERα-397 PvuII C/T* and *ERα-351 XbaI A/G* polymorphisms and their associated BC risk in Brazilian individuals.

Progesterone receptor
---------------------

Progesterone participates in the regulation of most female reproductive processes, targeting the ovaries (release of mature oocytes), uterus (promotion of implantation and maintenance of pregnancy), and mammary glands (suppression of lactation before parturition). The biological actions of progesterone are mediated by the progesterone receptor (PR), which belongs to the steroid-retinoic acid receptor superfamily and is encoded by a single copy gene located on chromosome 11q22-23 ([@B09]).

*PGR PROGINS polymorphism (rs1042838)*. One of the most widely studied polymorphisms in the *PGR* gene has been associated with abnormal gene expression and has a complex structure, consisting of a 306-bp *Alu* insertion in intron 7 and two sequence variations in exons 4 and 5 of the *PGR* gene, *Val*660*Leu* and *His*770*His* ([@B10],[@B11]).

The polymorphic allele has been denominated A2 and its wild-type counterpart, A1. Theoretically, women carrying the *A2 PGR PROGINS* allele would have an increased risk of developing malignancies in organs where progesterone exposure has a protective effect, such as ovary and endometrium ([@B12]). In the breast, where progesterone exposure has no protective effect, but rather stimulates cell proliferation, *PGR PROGINS* theoretically would reduce the risk of BC ([@B13]).

Although some studies have reported an association of *PGR PROGINS* with increased lifetime risk for developing BC ([@B14],[@B15]), data are conflicting and several other studies have shown an inverse relationship of the polymorphism with BC ([@B13],[@B16]). An overt protective effect of the *PR A2* allele was described by Wang-Gohrke et al. ([@B17]) in premenopausal women. The only Brazilian study on the association of *PGR PROGINS* with BC risk showed no statistically significant difference in its frequency between BC cases and controls ([@B18]).

Given the scarce data on the frequency and relevance of these polymorphisms in relation to BC risk in Brazilian women, the objective of the present study was to determine the genotypic and allelic frequencies of common *ER* and *PGR* gene polymorphisms and their relationship with BC risk factors in a sample of BC-unaffected women undergoing mammographic screening in an area with high BC incidence and mortality rates.

Material and Methods
====================

Study population
----------------

A consecutive and unselected sample of 750 BC-unaffected women (of a total of 890; age 40-69 years) enrolled in a mammography screening program in the city of Porto Alegre (Núcleo Mama Porto Alegre, NMPOA Cohort) was recruited for this study during routine mammographic visits between November 2005 and March 2006 ([@B19]). Study approval was obtained from the Ethics Committees of the participating institutions and all individuals recruited for the study gave written informed consent. Demographic and clinical information as well as results from mammographic screening were obtained from chart review.

Study variables
---------------

Study variables included age at recruitment, age at first childbirth, age at menarche and menopause, parity, BMI (classified into 3 categories: \<18.5; 18.5-24.99; 25-29.99; ≥30), self-reported skin color - assessed by self-denomination (white or non-white), results of the mammographic examination and mammographic density (using the BIRADS and breast density categories of the American College of Radiology), previous breast biopsies, use of HRT and/or oral contraceptives. Five-year and lifetime risk of developing BC was estimated using the Gail model ([@B20]).

Polymorphism analysis
---------------------

Genomic DNA was obtained from peripheral blood samples using a commercial DNA extraction kit (Illustra Blood genomicPrep Mini Spin Kit, GE Healthcare, UK). Genotyping was performed using the TaqMan PCR assay for *ERα-397 PvuII C/T* and *ERα-351 XbaI A/G* polymorphisms (rs2234693, C_3163590_10 and rs9340799, C_3163591_10, respectively; Applied Biosystems, USA), with fluorescent minor groove binding probes. Analyses were performed with an ABI 7500 real-time PCR system (Applied Biosystems), and results were analyzed with the Sequence Detection Software v 1.4 (Applied Biosystems). Genotyping of the *PGR PROGINS* polymorphism was based on the PCR amplification of a fragment encompassing the 306-bp insertion in intron 7. The *A1* allele was defined as "absence of the insertion", according to previous citations ([@B17]). The PCR products were resolved by agarose gel electrophoresis and visualized under UV light. The *A1* allele appeared as a 175-bp fragment and the *A2 PGR PROGINS* allele, as a 481-bp fragment.

Statistical analysis
--------------------

SPSS version 14.0 was used for data handling and statistical analyses. For descriptive analysis, categorical variables were described by their absolute and/or relative frequencies and quantitative variables are reported as means ± SD. For analytical statistics, the *t*-test for independent variables and ANOVA were used to compare the mean values of the quantitative variables. The existence of an association between categorical variables was examined by the chi-square test. The level of significance was set at 0.05 for all analyses. Comparative analysis of genotypic frequencies between this and other studies was done using WINPEPI (PEPI-for-Windows).

Results
=======

Data on BC risk factors identified in the sample of cancer-unaffected women is presented in [Table 1](#t01){ref-type="table"}. The allelic and genotypic frequencies of the *ERα-397 PvuII C/T*, *ERα-351 XbaI A/G* and *PGR PROGINS* polymorphisms in the overall sample, and in both white and non-white women followed Hardy-Weinberg equilibrium and no significant differences in allelic or genotypic frequencies were observed between white and non-white women ([Table 2](#t02){ref-type="table"}).

Table 1.Breast cancer risk factors in the sample studied (N = 750).VariableN (%)Mean ± SDAge at assessment (years)-51.0 ± 7.6Age at menarche (years)-12.8 ± 1.8Age at first childbirth (years)-22.0 ± 5.3Nulliparous31 (4.13)-Postmenopausal421 (56.1)-Age at menopause (years)-46.9 ± 5.5Use of hormone replacement118 (28.1)-Body mass index (kg/m^2^)-29.6 ± 5.8 \<18.56 (0.8)- ≥18.5-24.99158 (21.1)- 25-29.99273 (36.4)- ≥30308 (41.1)-Family history of breast cancer[\*](#TFN01t01){ref-type="table-fn"}100 (13.3)-Mammographic examination BIRADS 1 or BIRADS 2732 (97.6) BIRADS 39 (1.2) BIRADS 45 (1.1)Mammographic density Fatty breast tissue or moderately fatty breast tissue426 (56.8)- Moderately dense, dense or heterogeneously dense tissue324 (43.2)-Estimated lifetime risk of developing breast cancer (using the Gail model)-7.8 ± 3.3Previous breast biopsy40 (5.3)-[^1]

Table 2.Genotypic and allelic frequencies of the *ERα-397 PvuII C/T*, *ERα-351 XbaI A/G* and *PGR PROGINS* polymorphisms in the overall sample (N = 750), and in white (N = 599) and non-white women (N = 151).NameGenotypic frequencies, N (%)Allelic frequenciesP[\*](#TFN01t01){ref-type="table-fn"}HWE^\*\*^*ERα-397 PvuII C/TTTTCCCTC* Overall242 (32.3)356 (47.5)152 (20.2)0.560.44-1.000.74 White195 (32.5)286 (47.8)118 (19.7)0.560.44-0.50 Non-white47 (31.1)70 (46.4)34 (22.5)0.540.46-0.66*ERα-351 XbaI A/GAAAGGGAG* Overall347 (46.3)313 (41.7)90 (12.0)0.670.33-2.200.42 White270 (45.1)255 (42.6)74 (12.3)0.660.34-1.30 Non-white77 (51.0)58 (38.4)16 (10.6)0.700.30-1.00*PGR PROGINSA2A2A1A2A1A1A2A1* Overall15 (2.0)191 (25.5)544 (72.5)0.150.85-0.140.39 White13 (2.2)158 (26.4)428 (71.4)0.150.85-0.13 Non-white2 (1.3)33 (21.9)116 (76.8)0.120.88-0.04[^2]

The genotypic frequencies of all three polymorphism studied were significantly different from those described in other studies worldwide, but not different from frequencies published in a few studies with Brazilian BC-unaffected individuals (see Tables S1, S2, and S3).

Women with the *A2A2* and *A1A2 PGR PROGINS* genotypes had a higher average BMI compared to women with the *A1A1* genotype ([Table 3](#t03){ref-type="table"}). In addition, the *A2A2* and *A1A2 PR PROGINS* genotypes were encountered significantly more often in postmenopausal women with fatty and moderately fatty breast tissue. A significant association of the *GG* genotype with age at menarche (≥12 years) was found for the *ERα-351 XbaI A/G* polymorphism and its genotypes (*AA* + *AG* versus *GG*). No other significant associations of a particular genotype, or genotype combinations with the clinical characteristics of the women were found.

Table 3.Genotypes and breast cancer risk factors in the overall sample and in only postmenopausal women.*PGR PROGINS*VariableGenotypesP*A1A2* + *A2A2A1A1*Body mass index (mean ± SD) Overall (N = 750)30.3 ± 6.029.3 ± 5.70.041[\*](#TFN01t01){ref-type="table-fn"} Postmenopausal (N = 421)30.5 ± 6.029.3 ± 5.80.056[\*](#TFN01t01){ref-type="table-fn"}Mammographic density, N (%) Overall (N = 750)0.021[\#](#TFN03t03){ref-type="table-fn"}  A + B131 (63.6)295 (54.2)  C + D + E75 (36.4)249 (45.8) Postmenopausal (N = 421)0.044[\#](#TFN03t03){ref-type="table-fn"}  A + B99 (74.4)186 (64.6)  C + D + E34 (25.6)102 (35.4)*ERα-351 XbaI A/G*VariableGenotypesP*AA* + *AGGG*Menarche, N (%) Overall (N = 750)0.060[\#](#TFN03t03){ref-type="table-fn"}  \<12 years149 (22.6)17 (18.9)  12-13 years306 (46.5)34 (37.8)  ≥14 years203 (30.9)39 (43.3) Postmenopausal (N = 421)0.021[\#](#TFN03t03){ref-type="table-fn"}  \<12 years81 (22.1)8 (15.1)  12-13 years164 (44.7)17 (32.1)  ≥14 years122 (33.2)28 (52.8)[^3][^4][^5]

Finally, the haplotype frequencies of the *ERα-397 PvuII C/T* and *ERα-351 XbaI A/G* polymorphisms were assessed ([Table 4](#t04){ref-type="table"}). No significant association was observed between the breast cancer risk haplotype (*A-A-T-T*) versus other haplotypes in relation to breast density (P = 0.47), mean BMI (P = 0.90), mean estimated lifetime risk of developing BC (P = 0.12), and mean ages at menarche (P = 0.31) and menopause (P = 0.75).

Table 4.Frequencies of the *ERα-397 PvuII* and *ERα-351 XbaI* haplotypes.HaplotypesOriginCountryP*PXPxpXpx*N%N%N%N%Present study[\*](#TFN01t01){ref-type="table-fn"}BrazilBrazil0.13[\*\*](#TFN02t07){ref-type="table-fn"}40153.510714.320.324032.0Kobayashi et al., 1996 ([@B21])AsiaKorea\<0.014418.76326.510.313054.5Han et al., 1999 ([@B22])AsiaKorea\<0.0111018.512921.5142.334557.7Patel et al., 2000 ([@B23])EuropeCanada\<0.0123635.6639.50036354.9Becherini et al., 2000 ([@B24])EuropeItaly\<0.0124940.9355.781.331852.1Bagger et al., 2000 ([@B25])EuropeDenmark\<0.0115333.76013.30024153.0Albagha et al., 2001 ([@B26])EuropeUK\<0.016933.5199.2212.011656.1Yamada et al., 2002 ([@B27])AsiaKorea\<0.0141018.349922.300132959.4Van Meurs et al., 2003 ([@B28])Africa and USAUSA/Sub-Saharian Africa[\*\*\*](#TFN03t07){ref-type="table-fn"}0.641950.0313.600736.8[^6][^7][^8]

Discussion
==========

Normal breast tissue proliferation is very sensitive to the action of steroid hormones and their action is mediated by specific receptors. The current literature shows that, in certain populations, specific polymorphisms in hormone receptor genes may be associated with an increased risk of developing BC. Knowledge about the allelic and genotypic frequencies of such polymorphisms and their interaction with other BC risk factors may be helpful to identify women at higher risk for the disease. In this study conducted on a population-based sample of breast cancer-unaffected women, we describe the allelic and genotypic frequencies of selected polymorphisms in the *ER* and *PR* genes that have been previously shown to modify BC risk in other populations and describe their relationship with established BC risk factors.

The genotypic frequencies observed for the *PGR PROGINS* polymorphism were comparable to those reported in other studies on Brazilian and non-Brazilian populations ([@B12],[@B17],[@B18],[@B29],[@B30]). On the other hand, the genotypic frequencies of the *ERα* gene polymorphisms were significantly different from those described in most studies from other populations, emphasizing the importance of the population-specific determination of such frequencies ([@B02]-[@B05],[@B07],[@B31]-[@B33]).

No significant reproductive risk factors for BC were identified in the sample of women studied; i.e., mean age at menarche was above 12 years, mean age at first childbirth was well below age 30 years, mean age at menopause was below the age of 50 years and only a small proportion of women were nulliparous. However, mean BMI was above 25 and a significant proportion of women studied had a BMI ≥30.

Considering this unexpected prevalence of overweight and obesity in this unselected population-based sample of women, and that the *ERα* gene has been implicated in adiposity, lipid metabolism and feeding behavior, we also investigated a possible relationship between these polymorphisms and BMI, but no significant correlation was identified.

The progesterone receptor, the product of the *PGR* gene, mediates interactions between the estrogen, insulin and insulin growth factor (IGF) hormonal pathways and hyperinsulinemia, increased free IGF and increased circulating estrogen concentrations have each been associated with obesity in postmenopausal women ([@B34]). However, a direct association of this polymorphism with increased body weight remains elusive and additional studies are necessary to clarify the relevance of this observation and ultimately its relationship with increased BC risk.

*ERα-351 GG* genotype and age at menarche ≥12 years are in contrast to a previous report where menarche tended to occur 6 months later in girls with the *ERα-351 AA* genotype ([@B08]). It is well known that *ERα* gene polymorphisms can impact the maturation of the hypothalamic-pituitary-gonadal axis, which determines the onset of menarche and thus, although the exact biological mechanism explaining the relationship between *ERα-351 XbaI A/G* and age at menarche remains unknown, one could hypothesize that the association between *ERα-351 AA* genotype and increased BC risk could be influenced at least in part by reproductive features such as earlier age at menarche.

The distribution of *ERα-351 XbaI* and *ERα-397 PvuII* haplotypes was significantly different from that previously observed in populations of European and Asian ethnicity and approached that observed in only one previous study with a small sample of African and African-American individuals. This is an unexpected finding because, although the contemporary Brazilian population is highly admixed, the African contribution to the genetic pool in Southern Brazil is quite low, as compared to other regions of the country, with a clear predominance of European alleles. Price et al. ([@B35]), for instance, have estimated that African and European ancestry corresponds to 11 and 71% of the alleles in Brazilian individuals. Alves-Silva et al. ([@B36]), studying mitochondrial and nuclear alleles, had already described a differential distribution of Amerindian, African and European alleles and found a surprisingly high African and Amerindian contribution in white Brazilian individuals. However, in Southern Brazil, the major contribution was still European, both in mitochondrial (66%) and nuclear (79%) DNA. Thus, our observation of a haplotype distribution that is entirely different from all other reports in European populations is surprising and warrants further investigation. Finally, the observed frequency of the *px* haplotype, theoretically associated with an increased risk of BC, was the lowest among all studies published previously, and the inverse was observed for the *PX* haplotype.

Although a few significant associations between selected *ER* and *PR* polymorphisms and BC risk factors were identified in this population-based sample of women from a region with a high BC incidence rate, their exact role remains controversial and additional case-control studies are necessary to determine if they are indeed associated with an increased risk for the disease. Finally, if confirmed in other populations, the associations found in this study could have important implications for mammographic screening strategies.
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[^1]: Family history (FH) of breast cancer - if one of these questions was positive: 1) FH of breast or ovarian cancer in 1st degree relatives; 2) FH of bilateral breast cancer; 3) any man in the family with breast cancer; 4) any woman in the family with breast and ovarian cancer; 5) any woman in the family with breast cancer before the age of 50 years; 6) 2 or more relatives with breast and/or ovarian cancer; 7) 2 or more relatives with breast and/or bowel cancer.

[^2]: P = white versus non-white (chi-square test). ^\*\*^HWE = Hardy-Weinberg equilibrium (chi-square test).

[^3]: Mammographic density categories: A = fatty breast tissue; B = moderately fatty breast tissue; C = moderately dense breast tissue; D = dense; E = heterogeneously dense.

[^4]: *t*-test.

[^5]: Chi-square.

[^6]: Haplotype definitions and frequencies obtained in the present study: *PX* = *C-C-G-G* (N = 87, 11.6%); *C-C-G-A* (N = 57, 7.6%); *C-T-G-G* (N = 3, 0.4%); *C-T-G-A* (N = 254, 33.9%). *Px* = *C-C-A-A* (N = 8, 1.1%); *C-T-A-A* (N = 99, 13.2%). *pX* = *T-T-G-G* (N = 0, 0%); *T-T-G-A* (N = 2, 0.3%). *pX* = *T-T-A-A* (N = 240, 32.0%).

[^7]: P (chi-square test) between white and non-white women in the present study.

[^8]: Ten samples from African-American individuals and 9 samples from African individuals deposited in the Coriell Institute (Camden, NJ, USA).
